Module 3: Navigating the complex patient pathway in NSCLC without an oncogenic driver - ESMO-IO 2018
Learning Objectives Introduction

Introduction

Watch an internationally renowned faculty discuss the changing treatment paradigms in advanced NSCLC, including the current and future role of immunotherapy.

Dr. Maria Chiara Garassino and Dr. Maurice Pérol, discuss recent developments in clinical research and how these can be translated into clinical practice. Professor Enriqueta Felip and Professor Sanjay Popat (Chair) then provide insight on the future management of patients with advanced NSCLC using clinical case studies.

The information in this activity is intended for oncologists, nurses, and other healthcare professionals involved in the treatment of patients with lung cancer.

This ACCME-accredited touchSATELLITE SYMPOSIUM was recorded live during the ESMO Immuno-Oncology Congress in December 2018. The live voting content is no longer active for this symposium.

Learning objectives

After watching this touchSATELLITE SYMPOSIUM, you should:

1 AMA PRA Category 1 Credits™
Date of original release: March 7, 2019
Date credits expire: March 7, 2020 

Back to Education Zone

touchSATELLITE SYMPOSIUM

Harnessing the power of immunotherapy in advanced non-small cell lung cancer:
how do we navigate the increasingly complex patient pathway without an oncogenic driver?

1 AMA PRA Category 1 Credits™
Date of original release: March 7, 2019
Date credits expire: March 7, 2020 

Module 3: Navigating the complex patient pathway in NSCLC without an oncogenic driver

Professor Enriqueta Felip, MD and Professor Sanjay Popat, FRCP PhD present two interactive cases covering the practical aspects of patient management, including diagnosis, treatment selection, adverse event management and refractory/aggressive disease.

Key Learnings

Please test your knowledge about the information presented. The following questions will need to be completed to progress.

Q1. The patient in Case 1 was a 57-year old woman with a 50 pack-years history of smoking and a diagnosis of lung adenocarcinoma. What would be the most appropriate molecular testing to carry out in this patient, assuming all tests are available in your practice?

EGFR, ALK, ROS1, BRAF
BCRA1, BCRA2, BRAF
EGFR, HER2
EGFR, HER2, ROS1

Molecular diagnostics-guided targeted therapies have become a standard treatment for patients with lung cancer. NSCLC is a genomically complex disease that is characterized by the presence of therapeutically relevant genomic alterations in the majority of tumours that undergo comprehensive molecular testing. EGFR mutations in NSCLC are present in 10% to 15% of patients with advanced disease. Recurrent gene rearrangements involving ALK and ROS1, are also important drivers of tumour growth in lung cancer. ALK rearrangements occur in approximately 3% to 5% of lung adenocarcinomas and ROS1 fusions are each found in approximately 1% to 2% of unselected lung cancers. BRAF is another driver mutation found in lung adenocarcinomas.11

Molecular diagnostics-guided targeted therapies have become a standard treatment for patients with lung cancer. NSCLC is a genomically complex disease that is characterized by the presence of therapeutically relevant genomic alterations in the majority of tumours that undergo comprehensive molecular testing. EGFR mutations in NSCLC are present in 10% to 15% of patients with advanced disease. Recurrent gene rearrangements involving ALK and ROS1, are also important drivers of tumour growth in lung cancer. ALK rearrangements occur in approximately 3% to 5% of lung adenocarcinomas and ROS1 fusions are each found in approximately 1% to 2% of unselected lung cancers. BRAF is another driver mutation found in lung adenocarcinomas.10

Molecular diagnostics-guided targeted therapies have become a standard treatment for patients with lung cancer. NSCLC is a genomically complex disease that is characterized by the presence of therapeutically relevant genomic alterations in the majority of tumours that undergo comprehensive molecular testing. EGFR mutations in NSCLC are present in 10% to 15% of patients with advanced disease. Recurrent gene rearrangements involving ALK and ROS1, are also important drivers of tumour growth in lung cancer. ALK rearrangements occur in approximately 3% to 5% of lung adenocarcinomas and ROS1 fusions are each found in approximately 1% to 2% of unselected lung cancers. BRAF is another driver mutation found in lung adenocarcinomas.10

Molecular diagnostics-guided targeted therapies have become a standard treatment for patients with lung cancer. NSCLC is a genomically complex disease that is characterized by the presence of therapeutically relevant genomic alterations in the majority of tumours that undergo comprehensive molecular testing. EGFR mutations in NSCLC are present in 10% to 15% of patients with advanced disease. Recurrent gene rearrangements involving ALK and ROS1, are also important drivers of tumour growth in lung cancer. ALK rearrangements occur in approximately 3% to 5% of lung adenocarcinomas and ROS1 fusions are each found in approximately 1% to 2% of unselected lung cancers. BRAF is another driver mutation found in lung adenocarcinomas.10

Next Question

You completed: Module 3: Navigating the complex patient pathway in NSCLC without an oncogenic driver

REFERENCES